Illumina, Inc. (ILMN) Stock Price & Analysis
Illumina, Inc. (ILMN) closed at USD 269.4 on Thursday, October 22, 2026, down 4.76% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 269.4; the Oct 22, 2026 session ranged USD 257.31–283.55 on volume of 2,223,767 shares. Market capitalization is —, with a 52-week range of USD 94–309.35 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ILMN.md
Key facts (ILMN)
- Last four reported quarters (through Jun 28, 2026): revenue $4.49B, net income $825M (18.4% margin), free cash flow $931M (SEC filings).
- 2 of 80 tracked superinvestors hold ILMN (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 14 Form 4 filings, $592M; 6 not under a Rule 10b5-1 plan ($591M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.57 on a 1–5 scale) (21 analysts), mean target USD 245.8 (range 113–365).
- Total return with dividends: 1Y +169.5% vs S&P 500 +14.9%; 5Y -32.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD 1.36, revenue estimate $1.15B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ILMN)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $4.53B | $4.58B | $4.50B | $4.37B | $4.34B | $4.49B |
| Gross profit | $3.15B | $2.97B | $2.74B | $2.86B | $2.87B | — |
| Operating income | -$123M | -$4.18B | -$1.07B | -$833M | $807M | $882M |
| Net income | $762M | -$4.40B | -$1.16B | -$1.22B | $850M | $825M |
| EPS (diluted) | $4.90 | -$28.00 | -$7.34 | -$7.69 | $5.45 | — |
| Free cash flow | $337M | $106M | $283M | $709M | $931M | $931M |
| Gross margin | 69.7% | 64.8% | 60.9% | 65.4% | 66.1% | — |
| Operating margin | -2.7% | -91.2% | -23.7% | -19.1% | 18.6% | 19.6% |
| Net margin | 16.8% | -96.1% | -25.8% | -28.0% | 19.6% | 18.4% |
| Revenue growth | +39.7% | +1.3% | -1.7% | -2.9% | -0.7% | — |
| Cash + short-term investments | $1.34B | $2.04B | $1.05B | $1.22B | $1.63B | — |
| Total debt | $702M | $0K | $1.49B | $1.49B | $1.49B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 28, 2026) (ILMN)
P/E at fiscal year-ends: Dec 2025 24.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (ILMN)
2 of 80 tracked investors hold ILMN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Samantha McLemore | Patient Capital Management | 2.02% | $60.7M | Reduced -36.6% |
| Van Den Berg Management I | 1.62% | $7.7M | Reduced -2.6% |
Insider sales (SEC Form 4, open-market, last ~7 months) (ILMN)
8 of 14 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-02…2026-09-04 | Meister Keith A. | Director | 263,560 | $57.2M | 25.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-25…2026-08-27 | Meister Keith A. | Director | 375,941 | $85.2M | 26.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-19…2026-08-21 | Meister Keith A. | Director | 679,574 | $146M | 32.4% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-18 | Wedel Christensen Jakob | SVP, Strategy/Corp Development | 1,033 | $198K | 6.9% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-08-04…2026-08-05 | Meister Keith A. | Director | 741,127 | $148M | 26.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-30 | Davies Scott M | Chief Legal Officer | 615 | $123K | 2.9% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-25 | Davies Scott M | Chief Legal Officer | 615 | $111K | 2.9% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-05 | Leckman Patricia | SVP, Chief People Officer | 783 | $127K | 3.6% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-06-02 | Leckman Patricia | SVP, Chief People Officer | 784 | $127K | 3.4% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-28…2026-06-01 | Meister Keith A. | Director | 669,596 | $107M | 19.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-29 | Davies Scott M | Chief Legal Officer | 615 | $98K | 2.8% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-05-28…2026-05-29 | Ericksen Scott D | VP, Chief Accounting Officer | 2,000 | $305K | 12.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-13…2026-05-14 | Meister Keith A. | Director | 329,460 | $47.9M | 8.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-06 | Wedel Christensen Jakob | SVP, Strategy/Corp Development | 700 | $97K | 4.4% | Yes | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ILMN)
Consensus Hold (mean 2.57 on a 1–5 scale), 21 analysts; mean target USD 245.8 (low 113, high 365).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Canaccord Genuity | Target raised | Hold | $205 → $300 |
| 2026-10-13 | TD Cowen | Target raised | Hold | $210 → $270 |
| 2026-10-07 | Barclays | Target raised | Underweight | $160 → $200 |
| 2026-10-05 | RBC Capital | Target raised | Outperform | $230 → $310 |
| 2026-10-01 | Guggenheim | Target raised | Buy | $226 → $305 |
| 2026-09-29 | Leerink Partners | Target raised | Outperform | $220 → $300 |
| 2026-09-28 | Piper Sandler | Target raised | Overweight | $225 → $305 |
| 2026-09-09 | UBS | Upgrade | Neutral → Buy | $135 → $260 |
| 2026-09-03 | Argus Research | Target raised | Buy | $180 → $235 |
| 2026-08-03 | Canaccord Genuity | Target raised | Hold | $190 → $205 |
| 2026-08-03 | Citigroup | Target raised | Sell | $95 → $113 |
| 2026-08-03 | Piper Sandler | Target raised | Overweight | $200 → $225 |
Total return (dividends reinvested) (ILMN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +169.5% | -32.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +170.4% | -7.5% |
| Volatility (annualized) | 48.5% | 45.6% |
| Max drawdown | -25.7% (Jan 2026→Feb 2026) | -82.4% (Oct 2021→Apr 2025) |
ILMN revenue by business segment (quarter ended Jun 28, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Core Illumina | $1.16B | 100.0% | +9.4% |
| — Sequencing (part of Core Illumina) | $1.05B | 90.9% | +8.4% |
| — Microarray (part of Core Illumina) | $105.0M | 9.1% | +20.7% |
| Total revenue | $1.16B | 100% | — |
ILMN revenue by product line (quarter ended Jun 28, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Total product revenue | $982.0M | 84.7% | +7.7% |
| Consumables | $775.0M | 66.9% | +4.7% |
| Service | $177.0M | 15.3% | +20.4% |
| Instruments | $125.0M | 10.8% | +30.2% |
| Total revenue | $1.16B | 100% | — |
ILMN revenue by region (quarter ended Jun 28, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States and Canada | $653.0M | 56.3% | +14.8% |
| Europe, Middle East, Africa and Latin America | $368.0M | 31.8% | +3.7% |
| Asia-Pacific | $82.0M | 7.1% | +13.9% |
| Greater China | $56.0M | 4.8% | -11.1% |
| Total revenue | $1.16B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ILMN suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | GRAIL, Inc. (GRAL) | “Revenue from genotyping and sequencing services, including cancer detection testing services related to the GRAIL business prior to the Spin-Off, is recognized when earned, which is generally at the time the genotyping or sequencing analysis data is made available to the customer.” |
Quoted from the company's 10-K filed Feb 12, 2026.
Companies that name ILMN in their SEC reports
| Relationship to ILMN | Company | Filing | Sentence |
|---|---|---|---|
| supplier | FOXO TECHNOLOGIES INC. (FOXO) | 10-K Apr 15, 2026 | “recognizes revenue from collecting a royalty from Illumina, Inc. related to the sales of the Infinium Mouse Methylation Array.” |
| partner | STANDARD BIOTOOLS INC. (LAB) | 10-K Mar 16, 2026 | “On June 22, 2025, we entered into the Purchase Agreement with Illumina pursuant to which Illumina acquired the Disposed Entities.” |
| customer | GRAIL, Inc. (GRAL) | 10-K Mar 12, 2026 | “•We rely on Illumina, Inc. as a sole supplier for our next-generation sequencers and associated reagents, Madison Industries as a sole supplier of blood collection tubes, and Twist Bioscience Corporation as a sole supplier of DNA panels.” |
| customer | Caris Life Sciences, Inc. (CAI) | 10-K Mar 3, 2026 | “Supply Agreement with Illumina” |
| customer | Fulgent Genetics, Inc. (FLGT) | 10-K Feb 27, 2026 | “In particular, we rely on Illumina Inc., or Illumina, as the sole supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sole provider of maintenance and repair services for these sequencers; on Roche Holdings AG for certain laboratory equipment, supplies, and services for our immunohistochemistry services; on Leica Biosystems for an automated digital scan…” |
| customer | Personalis, Inc. (PSNL) | 10-K Feb 26, 2026 | “For example, we rely on Illumina as the sole supplier of sequencers and various associated reagents, and as the sole provider of maintenance and repair services for these sequencers.” |
| partner | VERACYTE, INC. (VCYT) | 10-K Feb 26, 2026 | “In 2023, we announced a multi-year agreement with Illumina, Inc. to also develop and offer some of our molecular tests in Canada, Europe, the Middle East, Asia Pacific and Latin America as decentralized IVD tests on their NextSeq 550Dx NGS instrument thereby leveraging the large installed base.” |
| customer | Adaptive Biotechnologies Corp (ADPT) | 10-K Feb 26, 2026 | “Any disruption in Illumina's operations or the suppliers of our reagents, materials or other equipment could impact our ability to do business.” |
| partner | CareDx, Inc. (CDNA) | 10-K Feb 25, 2026 | “In May 2018, we entered into a license and commercialization agreement with Illumina, which provides us with worldwide distribution, development and commercialization rights to Illumina's next generation sequencing product line for use in transplantation diagnostic testing.” |
| customer | Tempus AI, Inc. (TEM) | 10-K Feb 24, 2026 | “Illumina, Inc., is our primary supplier of sequencers and laboratory reagents; however, we purchase laboratory supplies from other companies as well, such as Roche Holdings, Inc., Integrated DNA Technologies, and Tecan US, Inc. We rely on standard commercial carriers for the delivery of samples to our laboratories.” |
| customer | GeneDx Holdings Corp. (WGS) | 10-K Feb 23, 2026 | “In addition, there are a large number of new entrants into the market for genetic information ranging from informatics and analysis pipeline developers to focused, integrated providers of genetic tools and services for health and wellness, including Illumina, Inc., which is also one of our suppliers.” |
| customer | Guardant Health, Inc. (GH) | 10-K Feb 19, 2026 | “In September 2014, we entered into a supply agreement with Illumina, Inc., or Illumina, for Illumina to provide products and services that can be used for certain research and clinical activities, including certain sequencers, reagents, and other consumables for use with the Illumina sequencers, as well as service contracts for the maintenance and repair of the sequencers.” |
ILMN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.36 | $1.36 | -0.4% | $1.15B | 19 |
| Next quarter (ends Dec 2026) | $1.54 | $1.49 | +3.0% | $1.22B | 17 |
| Current fiscal year (ends Dec 2026) | $5.36 | $5.23 | +2.5% | $4.62B | 21 |
| Next fiscal year (ends Dec 2027) | $6.13 | $5.93 | +3.3% | $4.92B | 21 |
ILMN options: expected move
Options price a move of about ±16.3% (±$43.95) by Nov 20, 2026, which includes earnings on Oct 29, 2026. Over the last 8 reports the stock moved ±10.4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 72.5% | ±16.3% |
| Dec 18, 2026 | 56 | 64.3% | ±20.2% |
| Jan 15, 2027 | 84 | 62.7% | ±24.1% |
| Mar 19, 2027 | 147 | 61.2% | ±30.8% |
| Jun 17, 2027 | 237 | 60.2% | ±38.2% |
30-day implied volatility 72.6% vs 57.1% realized over the last 30 trading days. Put/call ratio (volume) 1.41. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:49 UTC)
| Price | USD 269.4 |
|---|---|
| Change | ▼ 4.76% (down) |
| Previous Close | USD 269.4 |
| Open | USD 269.4 |
| Day Range | USD 257.31 – 283.55 |
| 52-Week Range | USD 94 – 309.35 |
| Volume | 2,223,767 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (ILMN)
Nexqual's technical model rates ILMN "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:49 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.29 (neutral) |
| vs SMA50 | Above (USD 240.27) |
| MACD | 8.39 (positive) |
Analyst Ratings (ILMN)
Wall Street analysts rate ILMN "Hold" based on 21 analysts, with a mean price target of USD 245.8 (range USD 113–365), per Nexqual as of October 23, 2026 at 09:49 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 245.8 |
| High Target | USD 365 |
| Low Target | USD 113 |
| Buy / Hold / Sell | 11 / 6 / 4 |
Earnings (ILMN)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD 1.36 |
| Revenue Estimate | $1.15B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.31 vs est 1.23 ▲ beat |
| 2026-03-31 | USD 1.15 vs est 1.05 ▲ beat |
| 2025-12-31 | USD 1.35 vs est 1.23 ▲ beat |
| 2025-09-30 | USD 1.34 vs est 1.17 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financials & Fundamentals (ILMN)
| Total Revenue | $4.49B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.40% |
| Gross Margin | +67.93% |
| Operating Margin | +21.14% |
| Profit Margin | +18.34% |
| ROE | +32.34% |
| Debt / Equity | 0.89 |
| Current Ratio | 1.8 |
| Total Cash | $1.17B |
| Total Debt | $2.53B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $931.00M (20.7% of revenue) |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financial Health Score (ILMN)
Nexqual rates Illumina, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:49 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 21% (last 12 months) |
| Balance Sheet | Mixed — $1.17B cash and investments vs $1.49B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $931M (last 4 quarters to Jun 2026, SEC), 21% margin |
| Efficiency | Strong — ROE 32%, ROA 8.7% |
Ownership (ILMN)
| Insider Ownership | +0.21% |
|---|---|
| Institutional Ownership | +107.66% |
| Shares Outstanding | 151.00M |
| Float | 150.50M |
| Short % of Float | +10.26% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Leadership (ILMN)
Illumina, Inc. is led by Jacob Thaysen, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:49 UTC.
| CEO, President & Director | Jacob Thaysen |
|---|---|
| Chief Financial Officer | Ankur Dhingra |
| Chief Technology Officer | Steven Barnard |
| Chief Strategy & Corporate Development Officer | Jakob Wedel |
Major Backers & Investors (ILMN)
Notable institutional backers of Illumina, Inc. include Capital Group, WCM Investment Management, LLC, FMR, LLC, according to Nexqual as of October 23, 2026 at 09:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 10.22% |
| WCM Investment Management, LLC | 4.11% |
| FMR, LLC | 3% |
| AQR Capital Management, LLC | 2.35% |
| Primecap Management Company | 2.33% |
| Growth Fund of America | 1.45% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.71% |
| Vanguard Group | 8.75% |
| State Street | 4.31% |
| Geode Capital | 1.95% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
From Illumina, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Our DRAGENTM Bio-IT Platform is used for secondary analysis and analyzes sequencing data from a variety of experiment types, including whole genomes, whole exomes, germline and somatic datasets, and RNA sequencing experiments with industry leading accuracy, speed and efficiency.
- Most of our product sales consist of sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation, based on our proprietary technologies.
- Our DNA sequencing technology is based on our proprietary reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis (SBS) biochemistry.
- In January 2025, we launched Illumina Single Cell 3' RNA Prep, a simple, end-to-end single cell workflow allowing transcriptome studies of hundreds to millions of cells.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IDXX | IDEXX Laboratories, Inc. | USD 566.76 | ▲ 2.4% |
| WAT | Waters Corporation | USD 455.59 | ▼ 0.41% |
| IQV | IQVIA Holdings, Inc. | USD 278.32 | ▲ 0.61% |
| A | Agilent Technologies, Inc. | USD 173.89 | ▼ 2.17% |
| MTD | Mettler-Toledo International, I | USD 1,684.64 | ▲ 0.4% |
| NTRA | Natera, Inc. | USD 401.37 | ▼ 2.91% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt